Format

Send to

Choose Destination
See comment in PubMed Commons below
ScientificWorldJournal. 2011;11:1981-94. doi: 10.1100/2011/590175. Epub 2011 Oct 26.

Update on chemotherapy in the treatment of urothelial carcinoma.

Author information

1
Moores UCSD Cancer Center, University of California, San Diego, 3855 Health Sciences Drive Mail Code 0987, San Diego, CA 92093-0987, USA.

Abstract

Urothelial carcinoma is the fifth most common malignancy diagnosed each year in the United States. Neoadjuvant and adjuvant chemotherapy are given to decrease the risk of recurrent or metastatic disease with the more robust clinical data supporting the former. Bladder preservation utilizes a trimodality approach with maximal transurethral resection followed by concurrent chemotherapy and radiation and is appropriate for select patients. Gemcitabine and cisplatin is the current standard of care for first-line treatment in fit patients with metastatic disease. Optimal second-line therapy remains undefined, and targeted agents are under investigation. Clinical trial participation should be encouraged in patients with urothelial carcinoma of the bladder to help improve treatment regimens and outcomes. Synopsis. Chemotherapy is commonly used in the treatment of urothelial carcinoma of the bladder. This paper will review the role of chemotherapy in the neoadjuvant, adjuvant, bladder sparing, and metastatic settings.

KEYWORDS:

Bladder cancer; Chemotherapy; Urothelial carcinoma

PMID:
22125450
PMCID:
PMC3217602
DOI:
10.1100/2011/590175
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Hindawi Publishing Corporation Icon for PubMed Central
    Loading ...
    Support Center